Semaglutide
Semaglutide (Ozempic / Wegovy)
A GLP-1 receptor agonist with robust clinical trial data for weight management and type 2 diabetes.
Semaglutide is FDA-approved as Ozempic (type 2 diabetes) and Wegovy (chronic weight management). This page discusses the compound in a research context. The approved forms are prescription-only and should be used under physician supervision. Research-grade semaglutide sold by compound vendors is not the same as the FDA-approved product and is not approved for human use in that form.
What it is
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It mimics GLP-1, a hormone that regulates insulin secretion, slows gastric emptying, and reduces appetite.
Unlike most peptides on this platform, semaglutide has FDA approval (Ozempic for diabetes, Wegovy for weight management) and extensive published clinical trial data in humans.
What research shows
- Average 15–17% body weight reduction in STEP trial series (Wegovy, 2.4mg weekly)
- Significant HbA1c reduction in type 2 diabetes
- 20% reduction in major cardiovascular events (SELECT trial)
- Reduced alcohol cravings and compulsive behaviors in early studies
- Potential renal protective effects in early research
What remains unknown
- Long-term effects beyond 2-year trial windows
- Weight regain dynamics after discontinuation — most weight returns within 1 year
- Optimal maintenance or cycling protocols
- Full mechanisms behind appetite changes beyond GLP-1 receptor signaling
Administration basics
Common use cases
Weight management, type 2 diabetes, cardiovascular risk reduction.
Half-life
~1 week (designed for once-weekly dosing).
Administration
Subcutaneous injection once weekly. Available as FDA-approved drug and as compounded versions.
Research Protocols & Common Usage
Doses used in research
- FDA-approved starting dose is 0.25mg/week subcutaneously for 4 weeks
- STEP trials titrated to 2.4mg/week over 16–20 weeks for weight loss (Wegovy)
- Ozempic (diabetes) titrates to 0.5–1mg/week
Administration routes studied
Typical protocol duration
STEP trials ran 68 weeks. Clinical use is generally long-term with ongoing monitoring.
Common stacking protocols
- Semaglutide is typically used as a standalone medication given its potency
- Should not be combined with other GLP-1 agonists
Contraindications & combinations to avoid
- Personal or family history of medullary thyroid carcinoma (MTC) — black box warning
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — contraindicated
- History of pancreatitis
- Should never be combined with other GLP-1 agonists (liraglutide, tirzepatide)
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with Semaglutide and what to avoid.
Track your Semaglutide protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the Semaglutide page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.